StreetInsider.com News Articles

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Thu, 18 Dec 2025 04:00:00 -0500

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke severity, prior to treatment in patients enrolled in Argenica Therapeutic's Phase II study of neuroprotective ARG-007
Brainomix AI core lab uses regulatory cleared stroke technology, alongside its foundation-model-powered imaging pipeline for clinical trials, to provide robust baseline phenotyping and efficacy analysis
The Brainomix AI-enabled analysis demonstrated efficacy of Argenica's ARG-007 in severe stroke patients
Findings from the analysis will inform future clinical development and patient selection to advance treatment options for patients with severe acute ischemic stroke

CHICAGO and

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Thu, 18 Dec 2025 04:00:00 -0500

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke severity, prior to treatment in patients enrolled in Argenica Therapeutic's Phase II study of neuroprotective ARG-007
Brainomix AI core lab uses regulatory cleared stroke technology, alongside its foundation-model-powered imaging pipeline for clinical trials, to provide robust baseline phenotyping and efficacy analysis
The Brainomix AI-enabled analysis demonstrated efficacy of Argenica's ARG-007 in severe stroke patients
Findings from the analysis will inform future clinical development and patient selection to advance treatment options for patients with severe acute ischemic stroke

CHICAGO and

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Thu, 18 Dec 2025 04:00:00 -0500

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke severity, prior to treatment in patients enrolled in Argenica Therapeutic's Phase II study of neuroprotective ARG-007
Brainomix AI core lab uses regulatory cleared stroke technology, alongside its foundation-model-powered imaging pipeline for clinical trials, to provide robust baseline phenotyping and efficacy analysis
The Brainomix AI-enabled analysis demonstrated efficacy of Argenica's ARG-007 in severe stroke patients
Findings from the analysis will inform future clinical development and patient selection to advance treatment options for patients with severe acute ischemic stroke

CHICAGO and

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Thu, 18 Dec 2025 04:00:00 -0500

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke severity, prior to treatment in patients enrolled in Argenica Therapeutic's Phase II study of neuroprotective ARG-007
Brainomix AI core lab uses regulatory cleared stroke technology, alongside its foundation-model-powered imaging pipeline for clinical trials, to provide robust baseline phenotyping and efficacy analysis
The Brainomix AI-enabled analysis demonstrated efficacy of Argenica's ARG-007 in severe stroke patients
Findings from the analysis will inform future clinical development and patient selection to advance treatment options for patients with severe acute ischemic stroke

CHICAGO and

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Thu, 18 Dec 2025 04:00:00 -0500

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke severity, prior to treatment in patients enrolled in Argenica Therapeutic's Phase II study of neuroprotective ARG-007
Brainomix AI core lab uses regulatory cleared stroke technology, alongside its foundation-model-powered imaging pipeline for clinical trials, to provide robust baseline phenotyping and efficacy analysis
The Brainomix AI-enabled analysis demonstrated efficacy of Argenica's ARG-007 in severe stroke patients
Findings from the analysis will inform future clinical development and patient selection to advance treatment options for patients with severe acute ischemic stroke

CHICAGO and

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Thu, 18 Dec 2025 04:00:00 -0500

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke severity, prior to treatment in patients enrolled in Argenica Therapeutic's Phase II study of neuroprotective ARG-007
Brainomix AI core lab uses regulatory cleared stroke technology, alongside its foundation-model-powered imaging pipeline for clinical trials, to provide robust baseline phenotyping and efficacy analysis
The Brainomix AI-enabled analysis demonstrated efficacy of Argenica's ARG-007 in severe stroke patients
Findings from the analysis will inform future clinical development and patient selection to advance treatment options for patients with severe acute ischemic stroke

CHICAGO and

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Thu, 18 Dec 2025 04:00:00 -0500

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke severity, prior to treatment in patients enrolled in Argenica Therapeutic's Phase II study of neuroprotective ARG-007
Brainomix AI core lab uses regulatory cleared stroke technology, alongside its foundation-model-powered imaging pipeline for clinical trials, to provide robust baseline phenotyping and efficacy analysis
The Brainomix AI-enabled analysis demonstrated efficacy of Argenica's ARG-007 in severe stroke patients
Findings from the analysis will inform future clinical development and patient selection to advance treatment options for patients with severe acute ischemic stroke

CHICAGO and

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Thu, 18 Dec 2025 04:00:00 -0500

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke severity, prior to treatment in patients enrolled in Argenica Therapeutic's Phase II study of neuroprotective ARG-007
Brainomix AI core lab uses regulatory cleared stroke technology, alongside its foundation-model-powered imaging pipeline for clinical trials, to provide robust baseline phenotyping and efficacy analysis
The Brainomix AI-enabled analysis demonstrated efficacy of Argenica's ARG-007 in severe stroke patients
Findings from the analysis will inform future clinical development and patient selection to advance treatment options for patients with severe acute ischemic stroke

CHICAGO and

Form D/A Algernon Health Inc.

Tue, 09 Dec 2025 12:01:00 -0500

si-local-file:///var/storage/secattach/20251209/25717092.html

Form D Algernon Health Inc.

Mon, 01 Dec 2025 16:43:00 -0500

si-local-file:///var/storage/secattach/20251201/25683372.html

Aegon explores asset sales outside US to sharpen market focus - Bloomberg

Wed, 26 Nov 2025 12:54:22 -0500

Aegon Ltd. (NYSE: AGN) is considering the sale of operations outside the United States as the Dutch insurer seeks to concentrate on its largest market, according to Bloomberg reporting, citing people familiar with the matter.

The company is working with financial advisers to evaluate potential divestments, said the people, who requested anonymity discussing an ongoing process. Aegon UK, which administers retirement accounts, is among the units being reviewed for potential sale.

The insurer is also considering divesting its 51% stake in a joint venture with Banco Santander SA (NYSE: SAN) that distributes insurance products in Spain and Portugal, some of the people

Aegon explores asset sales outside US to sharpen market focus - Bloomberg

Wed, 26 Nov 2025 12:54:22 -0500

The insurer is also considering divesting its 51% stake in a joint venture with Banco Santander SA (NYSE: SAN) that distributes insurance products in Spain and Portugal, some of the people

Algernon Health raises $500,000 in private placement

Thu, 06 Nov 2025 07:04:44 -0500

Algernon Health Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) announced a non-brokered private placement for gross proceeds of $500,000. The Vancouver-based healthcare company will issue units at $0.07 per unit.

Each unit consists of one Class A common share and one-half common share purchase warrant. The full warrants allow holders to acquire common shares at $0.15 per share for 12 months from issuance, increasing to $0.25 per share for the following 12 months, then to $0.50 per share for 36 months thereafter.

The warrants include an acceleration clause. If common shares trade at $0.20 or higher on the Canadian Securities Exchange for

Algernon Health raises $500,000 in private placement

Thu, 06 Nov 2025 07:04:44 -0500

The warrants include an acceleration clause. If common shares trade at $0.20 or higher on the Canadian Securities Exchange for

Algernon Health raises $500,000 in private placement

Thu, 06 Nov 2025 07:04:44 -0500

The warrants include an acceleration clause. If common shares trade at $0.20 or higher on the Canadian Securities Exchange for

Algernon Health Announces Private Placement

Thu, 06 Nov 2025 07:04:00 -0500

VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce a non-brokered private placement for gross proceeds of $500,000 (the “Offering”) of units (the “Units”) at an issue price of $0.07 per Unit.

Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and one-half Common Share purchase warrant (a “Common Warrant”). Each full Common Warrant will entitle the holder to acquire one Common Share (a “Common

Algernon Health Announces Private Placement

Thu, 06 Nov 2025 07:04:00 -0500

Algernon Health Announces Private Placement

Thu, 06 Nov 2025 07:04:00 -0500

Algernon Health Announces Private Placement

Thu, 06 Nov 2025 07:04:00 -0500

Algernon Health Announces Private Placement

Thu, 06 Nov 2025 07:04:00 -0500

Algernon Health Announces Private Placement

Thu, 06 Nov 2025 07:04:00 -0500

Algernon Pharmaceuticals changes name to Algernon Health

Wed, 15 Oct 2025 07:00:45 -0500

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) completed its name change to Algernon Health Inc., the Canadian healthcare company announced October 15. The company's common shares will begin trading under the new name on the CSE at market open on October 20, 2025.

The shares will trade under the new name with a new CUSIP number (01559C106) and ISIN (CA01559C1068), while the stock symbol remains unchanged. No action is required by shareholders regarding the name change.

The company said the name change reflects its focus on the Alzheimer's disease diagnostic market with plans to establish neuroimaging clinics across North America.

Algernon Pharmaceuticals changes name to Algernon Health

Wed, 15 Oct 2025 07:00:45 -0500

The company said the name change reflects its focus on the Alzheimer's disease diagnostic market with plans to establish neuroimaging clinics across North America.

Algernon Pharmaceuticals changes name to Algernon Health

Wed, 15 Oct 2025 07:00:45 -0500

The company said the name change reflects its focus on the Alzheimer's disease diagnostic market with plans to establish neuroimaging clinics across North America.

Algernon Pharmaceuticals Completes Name Change to Algernon Health

Wed, 15 Oct 2025 07:00:00 -0500

VANCOUVER, British Columbia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it has completed its previously announced name change to Algernon Health Inc. The Company’s common shares will begin trading under the new name on the CSE at market-open on Monday, October 20, 2025. The common shares will trade under the new name with a new CUSIP number, but the stock symbol will remain the same.

In connection with the name change, the following new CUSIP